2016 Index: from findings to change
Thursday, 17 November 2016
Access to Medicine Index
The Foundation team has begun a series of discussions about the 2016 Access to Medicine Index. The aim is to help identify opportunities for turning Index findings into improvements in access. Meetings will be held with investors, industry and government representatives, donors and other stakeholders, in a series of meetings in London, New York, Paris, Basel, Washington DC and Tokyo.
The Foundation team has begun discussing the 2016 Access to Medicine Index and its findings with a range of people and organisations working to improve access to medicine for the poorest.
Role of industry
On Wednesday 16 November, Jayasree K. Iyer, Executive Director, spoke in a panel at the FT Pharmaceutical and Biotechnology Conference in London. Her talk addressed the role of the pharmaceutical industry in emerging markets, where barriers to access to medicine are significant. “There is an increased demand for pharma companies to do business differently in emerging markets,” said Jayasree. “Stakeholders are asking companies to take specific steps.” The 2016 Access to Medicine Index, published on Monday 14 November, found that pharmaceutical companies are making moderate progress when it comes to improving access to their products, notably in relation to research & development and pro-access licensing. Progress in other areas, however, is static.
View for investors
On Thursday 17 November, Goldman Sachs hosted an investor briefing about the Index at its London headquarters. In his opening remarks, Keyur Parekh, Executive Director of Pharmaceuticals Global Investment Research at Goldmans Sachs, framed access to medicine as a critical topic for pharma analysts. The Foundation team presented the Ranking and a selection of findings, including on R&D and affordability. The participants included sell-side and buy-side analysts, pharma-sector specialists and ESG-focused investors, as well as representatives of companies measured in the Index. The discussions touched on a wide range of topics, including how companies ranking positions could be informed by their exposure to access-related risks, for example around prices.
Upcoming investor briefings
- New York on Thursday, 1 December, at AllianceBernstein
- Zurich on Thursday, 8 December, at Kepler Cheuvreux Stadelhoferstrasse
- Paris on Thursday 15 December, at Amundi Asset Management Auditorium
For more information about the events, please contact Suzanne Wolf.
Discussion in the media
The latest ranking of pharmaceutical companies in the 2016 Access to Medicine Index has been covered broadly in the media, including explorations of the findings related to affordability, R&D, capacity building and strategy:
About the Access to Medicine Index
The Access to Medicine Index analyses the top 20 research-based pharmaceutical companies with products for high-burden diseases in low- and middle-income countries. The Index ranks these companies according to their efforts to improve access to medicine in seven areas of corporate behaviour, including pricing, patents, ethical behaviour and donations. It covers 107 low- and middle-income countries and 50 high-burden diseases, and examines eight types of products, from medicines to vaccines to diagnostics. The Index identifies best practices, highlights where progress is being made, and uncovers where critical action is still required. In this way, the Index provides both an incentive and a guide for pharmaceutical companies to do more to improve access to medicine. It is published every two years by the Access to Medicine Foundation, an independent non-profit organisation.
About the Access to Medicine Foundation
The Access to Medicine Foundation is a non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income countries by stimulating and guiding the pharmaceutical industry to play a greater role in improving access to medicine. The Foundation is funded by the Bill & Melinda Gates Foundation, the Dutch Ministry of Foreign Affairs and the UK Department for International Development. For ten years, the Foundation has been building consensus on the role for the pharmaceutical industry in improving access to medicine and vaccines. It published its first benchmark of industry activity in this area in 2008, in the first Access to Medicine Index. The fifth Access to Medicine Index will be published in 2016.